Fresenius SE & Co KGaA
FRE: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€11.00 | Wptsc | Mchvvzhy |
Fresenius SE to Replace CEO; Shares Still Attractively Valued
Narrow-moat Fresenius SE announced on Aug. 19 that CEO Stephan Sturm (59) will be replaced by Michael Sen (53), who is current head of injectable therapy segment Kabi, in early October. While investors may see this changing of the guard as a positive catalyst for Fresenius SE shares, we are not changing our EUR 52 fair value estimate. We continue to view the shares as attractively valued.